{
    "nct_id": "NCT04881240",
    "official_title": "A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "NA",
    "miscellaneous_criteria": "Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing\n\n* Age ≥ 18 years old\n* At least single haplotype matched (≥ 3/6) family member\n* HIV negative\n* For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed\n* Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance\n\nFor Cohort A only, identified recipient with relapsed and/or refractory CD19-positive leukemia\n\nFor Cohort B only, iIdentified recipient with relapsed and/or refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:\n\n* Relapsed and/or refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy\n* History of prior autologous leukapheresis failure\n* History of prior autologous CAR T-cell manufacturing failure\n* Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size/low weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis\n\nEligibility Criteria for Patients: Treatment\n\n* Age ≤ 21 years old\n* Relapsed and/or refractory CD19-positive leukemia*:\n\n  * Refractory disease (defined as any of the following):\n\n    * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n    * Refractory disease despite salvage therapy\n  * Relapsed disease (defined as any of the following):\n\n    * 2nd or greater relapse\n    * Any relapse after allogeneic hematopoietic cell transplantation (HCT)\n    * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT\n\nCD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy\n\n* Patient cohorts:\n\n  * Cohort A: patient has previously received a HCT from the selected CAR T-cell donor\n  * Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor.\n* For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing\n* Detectable medullary CD19-positive leukemia\n* Estimated life expectancy of ≥ 8 weeks\n* Karnofsky or Lansky performance score ≥ 50\n* No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms\n* If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:\n\n  * ≥ 3 months from HCT\n  * have recovered from prior HCT therapy\n  * have no evidence of active GVHD within prior 2 months\n  * have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion\n* Adequate cardiac function: left ventricular ejection fraction ≥ 40% or shortening fraction ≥ 25% (function may be supported by pharmacologic therapy)\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function: creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if < 2 years of age)\n* Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Total bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n* No history of HIV infection\n* No evidence of severe, uncontrolled bacterial, viral or fungal infection\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child bearing age:\n\n  * Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment AND Not lactating with intent to breastfeed\n* If sexually active, agreement to use birth control until 6 months after CAR T-cell infusion\n* No history of hypersensitivity reactions to murine protein-containing products\n* Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone ≤ 7 days prior to CAR T-cell infusion\n* Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))\n* Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion"
}